• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

CCG-63802

CAS No. 620112-78-9

CCG-63802 ( —— )

产品货号. M26640 CAS No. 620112-78-9

CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥462 有现货
10MG ¥786 有现货
25MG ¥1725 有现货
50MG ¥3200 有现货
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    CCG-63802
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins.
  • 产品描述
    CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins. CCG-63802 inhibits the interaction between RGS4 and Galpha with an IC50 value of 1.4 μM.(In Vitro):CCG-63802 showed selectivity among RGS proteins with a potency order of RGS 4 > 19 = 16 > 8 ? 7. CCG-63802 inhibited the GTPase accelerating protein activity of RGS4.(In Vivo):The attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling was partially abrogated by administration of RGS4 inhibitor CCG-63802(0.5 mg/kg). The downregulation of RGS4 by CCG-63802 also significantly increased inflammatory cell accumulation and AHR, and increased levels of IL-4, IL-13, eotaxin, IFN-γ, and IL-17A in BALF, and total and OV-specific IgE in serum. The inhibitory effects of PGZ on the activations of ERK and Akt/mTOR signaling, and MMPs were apparently reversed by CCG-63802 administration.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Microtubule/Tubulin
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    620112-78-9
  • 分子量
    450.5
  • 分子式
    C26H18N4O2S
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Gardner ER, et al. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Invest New Drugs. 2012 Feb;30(1):90-7.
产品手册
关联产品
  • Boc-NH-PEG12-CH2CH2C...

    Boc-NH-PEG12-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • 2,6,4-Trihydroxy-4-m...

    2,6,4'-Trihydroxy-4-methoxybenzophenone shows weak inhibitory activity of testosterone 5alpha-reductase, it also shows significant inhibition of pancreatic lipase activity.

  • Buddlejasaponin IVb

    Buddlejasaponin IVb(200 uM) can shorten thrombin time (TT) by 20.6 %, suggests that it has hemostasis efficacy.